Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, will participate in two investor conferences in early December 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, will participate in two investor conferences in early December 2025.
Key events: Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 in New York, with a fireside chat at 8:00 AM ET and one-on-one meetings; and Evercore 8th Annual Healthcare Conference on December 3, 2025 in Coral Gables, with a fireside chat at 7:30 AM ET and one-on-one meetings. An audio webcast and a replay will be available via Biomea Fusion's News & Events page under Investors & Media.
Details
News Market Reaction – BMEA
On Nov 24, the day this news came out, BMEA closed 2.85% above the previous close.
Data tracked by StockTitan Argus for the Nov 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcoming investor conferences:
- Piper Sandler 37th Annual Healthcare Conference: Biomea will participate in a fireside chat at 8:00 AM (EST) and in one-on-one meetings on December 2, 2025 in New York, NY.
- 8th Annual Evercore Healthcare Conference: Biomea will participate in a Fireside Chat at 7:30 AM (EST) and in one-on-one meetings on December 3, 2025 in Coral Gables, FL.
An audio webcast of the presentations will be available here or by visiting the News & Events Page under the Investors & Media section of Biomea’s website. A replay of the webcasts will be available following the live event.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies for diabetes and obesity; icovamenib, a selective menin inhibitor for diabetes and BMF-650, a next generation oral GLP-1 receptor agonist for obesity. These programs target cardio metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.